IL181481A - Transporter Protein Containing Heavy Chain of Clostridium Botulinum Toxin A Modified to Insert Chemical Compounds into Nerve Cells - Google Patents

Transporter Protein Containing Heavy Chain of Clostridium Botulinum Toxin A Modified to Insert Chemical Compounds into Nerve Cells

Info

Publication number
IL181481A
IL181481A IL181481A IL18148107A IL181481A IL 181481 A IL181481 A IL 181481A IL 181481 A IL181481 A IL 181481A IL 18148107 A IL18148107 A IL 18148107A IL 181481 A IL181481 A IL 181481A
Authority
IL
Israel
Prior art keywords
introduction
heavy chain
chemical compounds
nerve cells
transport protein
Prior art date
Application number
IL181481A
Other languages
English (en)
Hebrew (he)
Other versions
IL181481A0 (en
Original Assignee
Syntaxin Ltd
Toxogen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Toxogen Gmbh filed Critical Syntaxin Ltd
Publication of IL181481A0 publication Critical patent/IL181481A0/en
Publication of IL181481A publication Critical patent/IL181481A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
IL181481A 2004-09-06 2007-02-21 Transporter Protein Containing Heavy Chain of Clostridium Botulinum Toxin A Modified to Insert Chemical Compounds into Nerve Cells IL181481A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004043009A DE102004043009A1 (de) 2004-09-06 2004-09-06 Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
PCT/EP2005/009554 WO2006027207A1 (de) 2004-09-06 2005-09-06 Transportprotein zum einbringen chemischer verbindungen in nervenzellen

Publications (2)

Publication Number Publication Date
IL181481A0 IL181481A0 (en) 2007-07-04
IL181481A true IL181481A (en) 2015-10-29

Family

ID=35583367

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181481A IL181481A (en) 2004-09-06 2007-02-21 Transporter Protein Containing Heavy Chain of Clostridium Botulinum Toxin A Modified to Insert Chemical Compounds into Nerve Cells

Country Status (19)

Country Link
US (3) US8293230B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1786832B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5357425B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101277280B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN101056888B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2005281830B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0514943A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2578097C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE102004043009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1786832T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA014526B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2390279T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL181481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN01950A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007002737A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO340732B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA93359C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006027207A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200701896B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264052A3 (en) 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
CA2578911A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
JP2008535486A (ja) * 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
BRPI0611752B8 (pt) 2005-06-17 2021-05-25 Merz Pharma Gmbh & Co Kgaa dispositivo e processo para produção fermentativa de compostos biologicamente ativos
EP2471550A1 (en) * 2005-10-07 2012-07-04 Health Protection Agency Proteins with improved solubility and methods for producing and using same
EP2038298A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543556A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
JP2008169166A (ja) * 2007-01-14 2008-07-24 Tokyo Univ Of Agriculture & Technology 糖結合性ポリペプチド、複合材料、及び薬剤送達システム
BRPI0812245A2 (pt) * 2007-06-01 2014-10-21 Merz Pharma Gmbh & Co Kgaa Método para provisão de um relaxante muscular termoestável com base no componente neurotóxico da toxina botulínica na forma sólida
US8617568B2 (en) * 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
WO2009015840A2 (en) * 2007-07-27 2009-02-05 Merz Pharma Gmbh & Co. Kgaa Polypeptide for targeting of neural cells
WO2009038770A2 (en) * 2007-09-20 2009-03-26 University Of Massachusetts Cvip Detoxified recombinant botulinum neurotoxin
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
WO2010014746A1 (en) * 2008-07-29 2010-02-04 Florida State University Research Foundation Materials and methods for treatment of spinal muscular atrophy and taxane-induced peripheral neuropathy (tipn)
AU2009286973B2 (en) 2008-08-29 2014-06-12 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency
ES2426667T3 (es) 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
HUE037310T2 (hu) 2012-05-30 2018-08-28 Harvard College Módosított botulinum neurotoxin
US9452205B2 (en) * 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CN104870468B (zh) 2012-11-21 2020-11-10 益普生生物创新有限公司 用于制备经蛋白水解处理的多肽的方法
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP2952205B1 (en) 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
PL3274364T3 (pl) 2015-03-26 2022-01-10 President And Fellows Of Harvard College Neurotoksyna botulinowa uzyskana technikami inżynierii
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10633643B2 (en) * 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
EP3341392A4 (en) 2015-08-27 2019-01-23 President and Fellows of Harvard College COMPOSITIONS AND METHODS OF PAIN TREATMENT
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
CN108348415B (zh) * 2015-11-20 2020-12-04 高露洁-棕榄公司 具有高纯偏磷酸盐磨料的单相增白洁齿剂
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
JP7118055B2 (ja) * 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
WO2019243376A1 (en) 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
EP3856923A1 (en) 2018-09-28 2021-08-04 Ipsen Biopharm Limited Cell-based clostridal neurotoxin assays
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
AU2022247196A1 (en) 2021-03-30 2023-10-05 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
KR20250060320A (ko) 2021-03-30 2025-05-07 입센 바이오팜 리미티드 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
JP2024534384A (ja) 2021-09-16 2024-09-20 イプセン バイオファーム リミテッド 頸部ジストニアを治療する用途の修飾ＢｏＮＴ／Ａ
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
JP2024534541A (ja) 2021-09-23 2024-09-20 イプセン バイオファーム リミテッド 被験体の眼瞼筋を冒す障害の治療における使用のための改変ＢｏＮＴ／Ａ
AU2022392458A1 (en) 2021-11-22 2024-05-02 Ipsen Biopharm Limited Treatment of pain
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
AU2023351434A1 (en) 2022-09-30 2025-03-06 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025093844A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
GB9410871D0 (en) 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6545126B1 (en) 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US7235521B1 (en) 1999-05-17 2007-06-26 United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
EP2264052A3 (en) * 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7196189B2 (en) 2001-10-09 2007-03-27 Microbia, Inc. love variant regulator molecules
US20070118934A1 (en) 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
KR20030097047A (ko) * 2002-06-18 2003-12-31 신찬영 초음파기화식냉풍기
GB0216865D0 (en) * 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US20050129677A1 (en) 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB2416692A (en) * 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
EP1778279B1 (en) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
JP4994241B2 (ja) 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
JP2008535486A (ja) 2005-03-15 2008-09-04 アラーガン、インコーポレイテッド クロストリジウム毒素標的細胞に対する改変された標的能力を有する修飾クロストリジウム毒素
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
EP1926744B2 (en) * 2005-09-19 2018-10-24 Allergan, Inc. Clostridial toxin activatable clostridial toxins
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
JP2009543556A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
WO2009042165A2 (en) 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain

Also Published As

Publication number Publication date
KR101277280B1 (ko) 2013-06-20
NO340732B1 (no) 2017-06-06
JP5357425B2 (ja) 2013-12-04
US9234011B2 (en) 2016-01-12
NO20071825L (no) 2007-06-06
WO2006027207A1 (de) 2006-03-16
AU2005281830B2 (en) 2011-12-22
DK1786832T3 (da) 2012-10-22
US20130116191A1 (en) 2013-05-09
BRPI0514943A (pt) 2008-07-01
EP1786832A1 (de) 2007-05-23
JP2008512089A (ja) 2008-04-24
JP5833039B2 (ja) 2015-12-16
US8293230B2 (en) 2012-10-23
HK1100291A1 (en) 2007-09-14
EA014526B1 (ru) 2010-12-30
KR20130043251A (ko) 2013-04-29
US9422344B2 (en) 2016-08-23
ES2390279T3 (es) 2012-11-08
KR20070059090A (ko) 2007-06-11
KR20140063901A (ko) 2014-05-27
JP2013139454A (ja) 2013-07-18
KR101602128B1 (ko) 2016-03-10
UA93359C2 (ru) 2011-02-10
ZA200701896B (en) 2009-05-27
CA2578097A1 (en) 2006-03-16
US20070299008A1 (en) 2007-12-27
IN2014DN01950A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-10
IL181481A0 (en) 2007-07-04
MX2007002737A (es) 2008-03-05
DE102004043009A1 (de) 2006-03-23
CA2578097C (en) 2014-05-20
CN101056888B (zh) 2012-07-04
EP1786832B1 (de) 2012-07-18
CN101056888A (zh) 2007-10-17
US20150030584A1 (en) 2015-01-29
EA200700408A1 (ru) 2007-08-31
AU2005281830A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
IL181481A (en) Transporter Protein Containing Heavy Chain of Clostridium Botulinum Toxin A Modified to Insert Chemical Compounds into Nerve Cells
IL180380A0 (en) Pharmaceutical composition containing botulinum neurotoxin
IL176382A0 (en) Method and compositions for detecting botulinum neurotoxin
PL2266544T3 (pl) Sposób wprowadzania substancji terapeutycznych do komórek
IL225848A0 (en) A medical preparation containing botulinum neurotoxin
EP1788081A4 (en) REAGENT CONTAINING PROTEASE REACTION PROMOTER AND / OR DYE STABILIZER
EP2021467A4 (en) CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
WO2005099770A3 (en) Pancreatic islet microrna and methods for inhibiting same
WO2007139898A3 (en) Variant foki cleavage half-domains
IL189149A (en) Botulinum nerve toxin a
EP1959994A4 (en) BOTULINUM NANOEMULSIONS
PL380395A1 (pl) Układ łańcuchowego napędu lub zwrotni, cięgno łańcuchowe i koło łańcuchowe, zwłaszcza górniczych urządzeń urabiających albo przenośnikowych
PL380303A1 (pl) Sposób urabiania węgla agregatem strugowym i agregat strugowy do urabiania węgla
WO2006132739A3 (en) Novel chemical compounds
PT1776137E (pt) Composição farmacêutica contendo a neurotoxina botulínica a2
WO2007030678A3 (en) Methods of genome-wide location analysis in stem cells
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
WO2006127458A3 (en) Novel chemical compounds
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
WO2007025190A3 (en) Novel methods for genome-wide location analysis
WO2007044115A3 (en) Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
IL184931A0 (en) Promoter of regeneration of pancreatic ?? cell, and promoter of insulin production in pancreatic ?? cell
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees